Akeso to Present 40+ Oncology Studies at ASCO 2026, Including Plenary Session on Ivonescimab
Event summary
- Akeso will present over 40 clinical studies at ASCO 2026, including one Late-Breaking Abstract selected for the Plenary Session.
- The HARMONi-6 study's Phase III overall survival results for ivonescimab in advanced squamous non-small cell lung cancer (sq-NSCLC) will be a key highlight.
- Additional presentations feature ivonescimab and cadonilimab across multiple tumor types, including small-cell lung cancer, metastatic colorectal cancer, and renal cell carcinoma.
- The studies underscore Akeso's innovation engine, demonstrating the clinical benefits of its differentiated bispecific antibody platform.
The big picture
Akeso's extensive presentation at ASCO 2026 highlights its aggressive push into the oncology market with its bispecific antibody platform. The focus on overall survival data and multiple tumor types positions the company to challenge existing treatments and potentially capture significant market share. The breadth of studies also underscores Akeso's ability to innovate and scale its pipeline, which is critical in the competitive biopharmaceutical landscape.
What we're watching
- Clinical Validation
- Whether the HARMONi-6 study's overall survival data for ivonescimab can position it as a frontline treatment for advanced sq-NSCLC.
- Market Differentiation
- How Akeso's bispecific antibody platform will compete against established and emerging therapies in the oncology space.
- Regulatory Pathway
- The pace at which Akeso can translate these clinical results into regulatory approvals and commercial success.
Related topics